The MHRA has further stated that the initial dose of TGN1412 was intended to be the first of a course of injections, with the dosage being ramped up over time. It has been reported that the initial dose was one five-hundredth of that which the animal studies indicated was a maximum safe dose. Dr. David Glover, an industry consultant, has suggested that because the antibody was raised against "human" CD28, the safe dosage may have been lower in humans than in animals. More concerningly, it has been shown that even using information available prior to the human first dose, it can be shown that the size of the initial dose was too high. Predictions showed that the 0.1 mg starting dose would bind to 86 to 91% of all CD28 receptors in the body, which means that even at the minimum starting dose selected, the investigators would anticipate seeing the maximum effect of the drug.